|
|
Post by harryx1 on May 14, 2015 16:37:21 GMT -5
|
|
|
|
Post by tarheelblue004 on May 14, 2015 17:39:03 GMT -5
|
|
|
|
Post by obamayoumama on May 14, 2015 18:35:42 GMT -5
Matt has stated to me that the small middle eastern country Al spoke about was in fact Saudi Arabia. If Sanofi wants to sell 200 million of Afrezza they need to chat with the Prince that called Al! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 14, 2015 18:58:45 GMT -5
Isn't the prince that called Al now the king?
|
|
|
|
Post by dwcarter654 on May 14, 2015 20:36:42 GMT -5
As SNY is already a global distributer and a member of the International Diabetes Federation, they may already have a registered representative in Saudi Arabia. This would put them ahead of the game with distribution approval.
|
|
|
|
Post by harryx1 on May 18, 2015 7:46:14 GMT -5
|
|
|
|
Post by babaoriley on May 18, 2015 9:28:18 GMT -5
Hot stuff, Harry! Foreign interest is such a huge deal! Love to see stuff like that!
I don't understand much Arabic, though, are you sure that guy wasn't saying that he developed Afrezza and the inhaler and that some infidel company in America was trying to pawn it off as theirs?
I, too, heard that the country Al was talking to years ago was SA, and I heard that only once removed from the horse's mouth, so I was pretty sure it was factual.
Almost forgot, loved the cameo by Sam! But Spiro's gonna be all over me for not getting him some exposure.
|
|
|
|
Post by benh on Jun 13, 2015 11:01:06 GMT -5
Ref: rewech.com/afrezza/ Stocktwits post. stocktwits.com/moe12/message/38232966 Translation Consultant endocrinologist, sugar and genetics, diabetes center in Asir Advisory Director of Mohammed bin Ahmed Alawad revealed that the FDA US recognized the new treatment of fast-acting insulin is a sprayer named «Afrezza» taken through the nose Bastnchagah to treat adults who suffer from diabetes, and are taken to control blood sugar. He »according to the newspaper Asharq al-Arabia The spray has been tested on a 3017 donor them in 1026 from patients with diabetes type I« Adults »and 1991 patients with diabetes type II« Adults »and continued the experiment 24 weeks to be used with insulin systematic long-acting Lantus and be insulin sprayer with meals and added «showed good results compared with fast-acting insulin needles. The scientific achievement and a change in the treatment of private-insulin-dependent diabetes needles, and Alawad pointed out that the US Food and Drug Administration (FDA) called for global cooperation on the report of the results of the use of this product, which is called .Afrezza He explained that the box contains a warning of use for people who are allergic to the chest or chronic obstructive pulmonary disease (COPD) as it is not correct to use it for those who have these diseases to the possibility of suffering severe cramps in the trachea or the like. I agree with Fuga. |
|
BIGWIG
Newbie
Posts: 15 
Sentiment: Long
|
Post by BIGWIG on Jun 13, 2015 17:40:05 GMT -5
|
|
|
|
Post by benh on Jun 14, 2015 12:48:06 GMT -5
To date they haven't manufacturered $200MM of product. I like good news. I like speculating about the potential of good news. But a site I can't verify, that struggles to get the basics right, is one that raises a red flag. |
|
